Potentiation of interferon induction of class I major histocompatibility complex antigen expression by human tumor necrosis factor in small cell lung cancer cell lines
- PMID: 2553249
Potentiation of interferon induction of class I major histocompatibility complex antigen expression by human tumor necrosis factor in small cell lung cancer cell lines
Abstract
The response of class I major histocompatibility complex antigen expression to in vitro administration of interferon and tumor necrosis factor alpha (TNF-alpha) was measured using class I major histocompatibility complex-deficient small cell lung cancer cell lines. Significant induction also was observed using gamma interferon (IFN-gamma) alone, whereas TNF-alpha alone yielded only modest induction. Classic small cell lung cancer cell lines NCI-H146 and NCI-H209 best demonstrated synergistic HLA and beta 2-microglobulin antigen induction with IFN-gamma and TNF-alpha with the following dose schedule: 3-6 days of TNF-alpha (200 units/ml) followed by 48 h of IFN-gamma (100 IU/ml). Induction was quantitated using an 125I-Protein A radioimmunoassay. Synergistic induction of the HLA and beta 2-microglobulin surface antigens on NCI-H146 was also possible with alpha interferon and TNF-alpha but required a higher concentration of the interferon, i.e., 3-6 days of TNF-alpha (200 units/ml) followed by 48 h of alpha interferon (1000 units/ml). Small cell lung cancer cell line NCI-H146 was further studied for expression of major histocompatibility complex messenger RNA using the optimal doses and sequence of addition of IFN-gamma and TNF-alpha as indicated above. A significant induction with IFN-gamma alone and synergistic induction with both IFN-gamma and TNF-alpha was quantitated for both HLA-A2 and beta 2-microglobulin transcripts using Northern blot analysis. Incubation with relatively low subcytotoxic doses of IFN-gamma and TNF-alpha also resulted in a marked synergistic decrease in c-myc message.
Similar articles
-
Induction of HLA class II antigens in osteosarcoma cells by interferons and tumor necrosis factor alpha.Anticancer Res. 1992 May-Jun;12(3):767-72. Anticancer Res. 1992. PMID: 1622136
-
Synergistic enhancement of class I major histocompatibility complex antigen expression in K562 cells induced by recombinant human interferon-gamma and tumor necrosis factor in combination.Exp Hematol. 1989 Aug;17(7):795-9. Exp Hematol. 1989. PMID: 2502422
-
Effects of tumor necrosis factor on the interferon-gamma-induced major histocompatibility complex class II antigen expression by human endothelial cells.Eur J Immunol. 1988 Sep;18(9):1469-72. doi: 10.1002/eji.1830180925. Eur J Immunol. 1988. PMID: 3139431
-
Tumor necrosis factor alpha: a multifaceted peptide hormone.Crit Rev Immunol. 1989;9(1):21-44. Crit Rev Immunol. 1989. PMID: 2539946 Review.
-
Cellular responses to interferon-gamma.Annu Rev Immunol. 1997;15:749-95. doi: 10.1146/annurev.immunol.15.1.749. Annu Rev Immunol. 1997. PMID: 9143706 Review.
Cited by
-
Small cell lung cancer cells express the late stage gBK tumor antigen: a possible immunotarget for the terminal disease.Am J Transl Res. 2014 May 15;6(3):188-205. eCollection 2014. Am J Transl Res. 2014. PMID: 24936214 Free PMC article.
-
Immunotherapy of cancer in 2012.CA Cancer J Clin. 2012 Sep-Oct;62(5):309-35. doi: 10.3322/caac.20132. Epub 2012 May 10. CA Cancer J Clin. 2012. PMID: 22576456 Free PMC article. Review.
-
Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention.Clin Dev Immunol. 2012;2012:160724. doi: 10.1155/2012/160724. Epub 2012 Jul 29. Clin Dev Immunol. 2012. PMID: 22899945 Free PMC article. Review.
-
Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha.Cancer Immunol Immunother. 1994 Feb;38(2):113-8. doi: 10.1007/BF01526206. Cancer Immunol Immunother. 1994. PMID: 8306366 Free PMC article. Clinical Trial.
-
Impairment of MHC class I transcription in a mutant bovine B cell line.Immunogenetics. 1992;35(1):1-8. doi: 10.1007/BF00216620. Immunogenetics. 1992. PMID: 1345904
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials